Pexiganan (MSI 78 free base) is a synthetic analog of magainin 2. Pexiganan is a potent and orally active broad-spectrum antimicrobial peptide. Pexiganan can be used in the research of infections, such as diabetic foot ulcer infections[1].
Pexiganan (MIC: 0-128 μg/mL approximately) shows broad-spectrum antibacterial activity against 3,109 clinical isolates of gram-positive and gram-negative, anaerobic and aerobic bacteria[2].
Pexiganan (4 μg/mL) inhibits gastric ulcer strain and gastric cancer strain[3].
Pexiganan (1, 3, 10 or 30 mg/kg, p.o., daily for three consecutive days) shows H. pylori clearance efficiency in H. pylori-infected mouse[3].
Pexiganan (1 mg/kg, i.p.) shows antimicrobial activity in rat models of Gram-negative septic shock[4].
| Animal Model: | H. pylori-infected mouse[3]. |
| Dosage: | 1, 3, 10 or 30 mg/kg |
| Administration: | Oral administration, daily for three consecutive days. |
| Result: | Lowered H. pylori urease activities in mouse stomachs. |
| Animal Model: | Rat models of Gram-negative septic shock (induced by E.coli ATCC 25922)[4]. |
| Dosage: | 1 mg/kg |
| Administration: | Intraperitoneal injection (i.p.) |
| Result: | Displayed antimicrobial activities and survival rates of 67.7%. |
[1]. Lamb HM, et al. Pexiganan acetate. Drugs. 1998 Dec;56(6):1047-52; discussion 1053-4.
[2]. Ge Y, et al. In vitro antibacterial properties of pexiganan, an analog of magainin. Antimicrob Agents Chemother. 1999 Apr;43(4):782-8.
[3]. Zhang XL, et al. The synthetic antimicrobial peptide pexiganan and its nanoparticles (PNPs) exhibit the anti-helicobacter pylori activity in vitro and in vivo. Molecules. 2015 Mar 2;20(3):3972-85.
[4]. Giacometti A, et al. Effects of pexiganan alone and combined with betalactams in experimental endotoxic shock. Peptides. 2005 Feb;26(2):207-16.